Latest Drotrecogin alfa Stories

DENVER, Jan. 24, 2013 /PRNewswire/ -- Medical Simulation Corporation's (MSC) SimSuite Sepsis Quality Initiative Program, focusing on the early identification and treatment of sepsis, is aligned with the Surviving Sepsis Campaign (SSC) guidelines. Following the January 20 release of the guidelines for management of patients with severe sepsis and septic shock, MSC is currently updating its sepsis curriculum and knowledge assessments to reflect the revised guidelines. MSC's updated...

As severe sepsis becomes a silent epidemic among the elderly, greater mental health screenings may be necessary for spouses Severe sepsis, a body’s dangerous defensive response against an infection, not only diminishes the quality of life for patients – it puts their spouses at a greater risk of depression, a joint University of Michigan Health System and University of Washington School of Medicine study shows. Wives whose husbands were hospitalized for severe sepsis were nearly...

(Ivanhoe Newswire) --A drug used to treat sepsis that was once pulled for poisoning the blood, may be effective after all. The drug, known as drotrecogin alfa (activated) was approved for use in the United States in 2001, and in Europe in 2002, on the basis of the randomized, double-blind, placebo-controlled PROWESS study. Experts were concerned about the drug's efficacy and side-effects, and a second clinical study led to Eli Lilly withdrawing the drug in October 2011. The FDA made a...

SAN DIEGO, Jan. 12, 2012 /PRNewswire/ -- Aethlon Medical, Inc. (OTCBB: AEMD), the pioneer in developing selective therapeutic filtration devices to address infectious disease, cancer and other life-threatening conditions, announced today that it has established a Sepsis & Inflammation Scientific Advisory Board to provide guidance on the development of new therapeutics, including a device to reduce the incidence of sepsis in combat-injured soldiers being advanced under a contract...

MONMOUTH JUNCTION, N.J., Jan. 11, 2012 /PRNewswire/ -- CytoSorbents Corporation (OTCBB:CTSO), a critical care focused company using blood purification to treat life-threatening illnesses, issued the following letter to shareholders. Dear Shareholders and Friends, 2011 was an outstanding year for CytoSorbents, marked by the achievement of numerous major milestones that have led to the first ever product revenue for the Company. Although modest, initial sales from our...

In the news release, Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance, issued Jan. 5, 2012 by Eli Lilly and Company over PR Newswire, we are advised by the company that the second paragraph, second sentence, should read "and $.18 of asset impairment " rather than "and $.13 of asset impairment" as originally issued inadvertently. The complete, corrected release follows: Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance...

INDIANAPOLIS, Jan. 5, 2012 /PRNewswire/ -- Company expects to meet or exceed 2011 EPS guidance. 2012 financial guidance reflects revenue and earnings declines due to Zyprexa patent expiration. 2012 revenue anticipated to be between $21.8 billion and $22.8 billion. Company expects to keep 2012 operating expenses essentially flat versus 2011. 2012 earnings per share forecasted to be in the range of $3.10 - $3.20. R&D pipeline includes 12 molecules in Phase III development at...

A recent study led by researchers at Boston University School of Medicine (BUSM) shows an increased risk of stroke and mortality among patients diagnosed with severe sepsis and new-onset atrial fibrillation (AF) during hospitalization. Allan J. Walkey, MD, assistant professor of medicine at BUSM and a pulmonologist at Boston Medical Center (BMC), is the lead author of the study, which will be published in the Journal of the American Medical Association. Walkey also will present the...

(Ivanhoe Newswire) – A new drug commonly used to treat bleeding events in people with severe hemophilia can also be used to prevent such events from happening at all, according to this study. An international research team led by Dr. Cindy Leissinger of Tulane University School of Medicine, along with Dr. Alessandro Gringeri from the University of Milan, examined the ability of FEIBA to prevent bleeds in people with severe hemophilia A with inhibitors. People with this condition produce...

INDIANAPOLIS, Oct. 25, 2011 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) has updated its full-year 2011 financial guidance as a result of the announced withdrawal of the company's Xigris® product. Lilly expects to incur a charge in the fourth quarter of 2011 for asset impairments and contractual commitments related to Xigris. The exact amount of the charge has not yet been determined, but is estimated to be in the range of $75.0 million to $95.0 million (pre-tax), or approximately...